In 2016, a phase Ib/IIa clinical trial was conducted to investigate the combinatorial effects of T-DM1 and docetaxel, and potentially pertuzumab, in patients with HER2-positive advanced breast cancer [152]. Here, ERBB2 is linked to breast cancer.